Supplement Scholar
Peptide

Tesamorelin (Ref)

Prescription drug or research compound. Use only under the care of a licensed prescriber. Information here is educational and not a recommendation to obtain or use it.

Tesamorelin (Ref). GHRH analog approved for HIV-associated visceral adiposity.

How it works. Stimulates endogenous GH release via pituitary GHRH receptor.

What the research supports. 1 graded claims. Strongest: Reduces visceral adipose tissue (strong).

How much to take. Typical dose: 2 mg SC daily (Rx).

Side effects and interactions. 1 medication interaction listed. Serious: Hyperglycemia.

Stacking. Pairs well with A high-quality multivitamin, Omega-3 (EPA/DHA).

Common forms. Available as Subcutaneous injection, Oral or sublingual lozenge, Nasal spray, Compounded topical.

Key studies. 8 studies cited. The strongest are listed with links to PubMed.

Community. Experiences from people who have tried Tesamorelin (Ref). Anecdotes are not medical advice.

Tesamorelin (Ref). GHRH analog approved for HIV-associated visceral adiposity.

No single structure

What it is

GHRH analog approved for HIV-associated visceral adiposity.

Food sources

Synthetic peptide manufactured to pharmaceutical or research-grade puritySubcutaneous injection, sublingual, or oral preparation depending on bioavailabilityCompounded by a licensed pharmacy for clinical use

Goals

Growth Hormone Support

How it works

Stimulates endogenous GH release via pituitary GHRH receptor.

Pathways

  • Stimulates endogenous GH release via pituitary GHRH receptor

Effects

  • ↓visceral adipose tissue decreases

What the research supports

Reduces visceral adipose tissuestrong

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Typical dose
2 mg SC daily (Rx)
TimingConsistent daily timing recommended; split larger doses if GI tolerance is a concern.
With foodEither with or without food.
Best formMost evidence is based on the subcutaneous injection form.

Side effects & interactions

Common side effects

  • Injection site reactions

Serious

  • Hyperglycemia

Medication interactions

Prescription medications (general)minor

Always disclose Tesamorelin (Ref) use to your prescriber — additive, antagonistic, or pharmacokinetic interactions are possible.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • A high-quality multivitaminCovers micronutrient cofactors that support most supplement pathways.
  • Omega-3 (EPA/DHA)Foundational anti-inflammatory support that complements most regimens.

Common forms

  • Subcutaneous injection
  • Oral or sublingual lozenge
  • Nasal spray
  • Compounded topical

Key studies

8 studies cited in total.

PubMed: Tesamorelin (Ref) — Reduces visceral adipose tissue ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Tesamorelin (Ref) and "Reduces visceral adipose tissue". Filter by RCT, meta-analysis, or year on the results page.

PubMed: Tesamorelin (Ref) — randomized controlled trial ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Tesamorelin (Ref) and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

PubMed: Tesamorelin (Ref) — meta-analysis ↗
Systematic review · PubMed (NLM) · 2026

Opens current human and preclinical literature matching Tesamorelin (Ref) and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

Discussion

Loading discussion…